Haematological safety of long-term therapy with linezolid

International Journal of Antimicrobial Agents

Volumn 29, Issue 4, 2007, Pages 480-483

  Garazzino, Silvia ^a   De Rosa, Francesco Giuseppe ^a   Bargiacchi, Olivia ^a   Audagnotto, Sabrina ^a   Maiello, Agostino ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM; LINEZOLID; QUINOLONE; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ANEMIA; CHEILITIS; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMATOLOGY; HUMAN; KAPLAN MEIER METHOD; LETTER; LONG TERM CARE; MALE; NAUSEA; ORAL PARESTHESIA; OSTEOMYELITIS; OUTPATIENT; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ACETAMIDES; ADULT; AGED; ANTI-INFECTIVE AGENTS; DRUG TOXICITY; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; OXAZOLIDINONES; PROSPECTIVE STUDIES; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA;

EID: 33847385377     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.12.007     Document Type: Letter

References (11)

1. Attassi K., Hershberger E., Alam R., and Zervos M.J. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 34 (2002) 695-698
2. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., and Schentag J.J. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36 (2003) 159-168
3. Gerson S., Kaplan S., Bruss J., et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46 (2002) 2723-2726
4. Waldrep T.W., and Skiest D.J. Linezolid-induced anaemia and thrombocytopenia. Pharmacotherapy 22 (2002) 109-112
5. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests, 9th ed. Approved standard. M02-A9; Wayne, PA: CLSI, 2006.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. M100-S16. Wayne, PA: CLSI, 2006.
7. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard. M07-A7. Wayne, PA: CLSI, 2006.
8. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 6th ed. Approved standard. M11-A6. Wayne, PA: CLSI, 2006.
9. Nasraway S.A., Shorr A.F., Kuter D.J., O'Grady N., Le V.H., and Cammarata S.K. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 11 (2003) 1609-1616
10. Rao N., Ziran B.H., Wagener M.M., Santa E.R., and Yu V.L. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 38 (2004) 1058-1064
11. Senneville E., Legout L., Valette M., et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 54 (2004) 798-802